Background
Methods
Setting and participants
Statistical analysis
Results
Patient characteristics
All patients | |
---|---|
Patients (n) | 682 |
Clinical characteristics | |
Gender (female) | 676 (99.12%) |
Age (mean years) | 62.5 (50.9–72.6) |
Body weight (mean kg ± SD) | 66.3 ± 13.6 |
Body Mass Index (n = 662) (mean kg/m2 ± SD) | 25.5 ± 5.0 |
Obesity | 107 (15.7%) |
Cancer characteristics | |
Breast side (left) | 357 (52.3%) |
UICC Breast Staging | |
O | 39 (0.7%) |
I | 327 (47.9%) |
II | 226 (33.1%) |
III | 75 (11.0%) |
IV | 15 (2.2%) |
Histological type | |
Infiltrating Ductal Carcinoma | 547 (80.2%) |
Infiltrating Lobular Carcinoma | 74 (10.9%) |
Carcinoma in situ | 39 (5.7%) |
Histopronostic criteria | |
Her2 positive | 78 (11.4%) |
Hormonal receptors positives | 565 (82.8%) |
Triple negative | 58 (8.5%) |
SBR 1–2 grade | 454 (66.6%) |
SBR 3 grade | 191 (28.0%) |
Cancer treatments | |
Surgery | 665 (97.5%) |
Chemotherapy | 256 (37.5%) |
Trastuzumab therapy | 60 (8.8%) |
Radiotherapy | 673 (98.7%) |
Hormone blocking therapy | 551 (80.8%) |
Cardiovascular characterics | |
Cardiovascular risk factors | 340 (49.9%) |
Hypertension | 251 (73.8%) |
Diabetes mellitus | 59 (17.4%) |
Smoking (current or stopped less than 2 years) | 53 (15.6%) |
Hypercholesterolemia | 119 (35%) |
Atrial fibrillation (AF) at cancer diagnosis | 22 (3.2%) |
Cardiovascular treatments at cancer diagnosis | 214 (31.4%) |
Β-blockers | 71 (10.4%) |
ACE inhibitor or AIIRAs | 100 (14.7%) |
CCB | 63 (9.2%) |
Diuretics | 69 (10.1%) |
Anticoagulant | 20 (2.9%) |
One antiplatelet | 40 (5.9%) |
Dual antiplatelets | 3 (0.43%) |
N = 682 | N (%) | |
---|---|---|
Chemotherapy (N = 682) | Y | 256 (37.5%) |
N | 426 (62.5%) | |
Neo-adjuvant chemotherapy (N = 682) | Y | 22 (3.2%) |
N | 660 (96.8%) | |
Adjuvant chemotherapy (N = 682) | Y | 234 (34.3%) |
N | 448 (65.7%) | |
Chemotherapy with anthracyclines (N = 256) | Y | 174 (68%) |
N | 82 (32%) | |
3 FEC 100–3 DOCETAXEL (N = 256) | Y | 74 (28.9%) |
N | 182 (71.1%) | |
6 TAC (N = 256) | Y | 79 (30.9%) |
N | 177 (69.1%) | |
6 FEC (N = 256) | Y | 1 (0.4%) |
N | 117 (45.7%) | |
4 AC-4 DOCETAXEL (N = 256) | Y | 19 (7.4%) |
N | 237 (92.6%) | |
4 AC-12 PACLITAXEL WEEKLY: (N = 256) | Y | 1 (0.4%) |
N | 255 (99.6%) | |
Chemotherapy without anthracyclines (N = 256) | Y | 82 (32%) |
N | 174 (68%) | |
6 DOCETAXEL-CARBOPLATINE (N = 256) | Y | 4 (1.6%) |
N | 251 (98%) | |
4 DOCETAXEL-ENDOXAN (N = 256) | Y | 78 (30.5%) |
N | 178 (69.5%) |
Cardiovascular disease events
N = 682 | Modality | No Event | Event |
---|---|---|---|
HER2 overexpression (N = 682) | Y | 551 (85%) | 25 (73.5%) |
N | 69 (10.6%) | 9 (26.5%) | |
NA | 28 (4.3%) | 0 (0%) | |
Left breast (N = 682) | Y | 340 (52.5%) | 17 (50%) |
N | 308 (47.5%) | 17 (50%) | |
NA | 0 (0%) | 0 (0%) | |
Triple negative status (N = 682) | N | 590 (91%) | 32 (94.1%) |
Y | 56 (8.6%) | 2 (5.9%) | |
NA | 2 (0.3%) | 0 (0%) | |
Metastatic at diagnosis (N = 682) | Inf IV | 634 (97.8%) | 33 (97.1%) |
IV | 14 (2.2%) | 1 (2.9%) | |
NA | 0 (0%) | 0 (0%) | |
UICC (N = 682) | <III | 573 (88.4%) | 19 (55.9%) |
> = III | 75 (11.6%) | 15 (44.1%) | |
NA | 0 (0%) | 0 (0%) | |
Chemotherapy with anthracyclines (N = 682) | Y | 162 (25%) | 12 (35.3%) |
N | 73 (11.3%) | 9 (26.5%) | |
NA | 413 (63.7%) | 13 (38.2%) | |
Hormonotherapy (N = 682) | Y | 525 (81%) | 26 (76.5%) |
N | 123 (19%) | 8 (23.5%) | |
NA | 0 (0%) | 0 (0%) | |
Pre-existing cardiovascular disease risk factors (N = 682) | N | 332 (51.2%) | 9 (26.5%) |
Y | 315 (48.6%) | 25 (73.5%) | |
NA | 1 (0.2%) | 0 (0%) |